Literature DB >> 21116314

The pathology of chronic allograft dysfunction.

Lorraine C Racusen1, Heinz Regele.   

Abstract

Chronic allograft dysfunction is associated with a variety of fibrosing/sclerosing changes in the allograft. Fibrosis is multifactorial, a final pathway following varying types of injury. Using a range of diagnostic criteria, the pathologist can and should define specific lesions enabling identification of pathogenic processes affecting the allograft. Although some cases remain 'interstitial fibrosis and tubular atrophy, no specific cause', specific diagnoses can be made in most cases. Drug toxicity, bacterial or viral infection, hypertension, obstruction, recurrent or de novo renal diseases, and acute and chronic cell- and/or antibody-mediated rejection can be diagnosed in this setting. Of particular concern is a combination of persistent inflammation and fibrosis, which has repeatedly been shown to be correlated with poor graft outcomes. Identification of ongoing activity, and the stage of evolution of fibrosis/sclerosis provides important diagnostic and therapeutic information for patient management. Histological, immunohistological, ultrastructural, and molecular studies may be needed to adequately assess the kidney in the setting of chronic allograft dysfunction. Protocol biopsies may provide diagnostic insights in early stages of late graft deterioration, or even before evident dysfunction develops.

Entities:  

Mesh:

Year:  2010        PMID: 21116314     DOI: 10.1038/ki.2010.419

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  22 in total

1.  The unfolded protein response regulates an angiogenic response by the kidney epithelium during ischemic stress.

Authors:  Nicolas Bouvier; Sophie Fougeray; Philippe Beaune; Eric Thervet; Nicolas Pallet
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

2.  MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways.

Authors:  B Nelson Chau; Cuiyan Xin; Jochen Hartner; Shuyu Ren; Ana P Castano; Geoffrey Linn; Jian Li; Phong T Tran; Vivek Kaimal; Xinqiang Huang; Aaron N Chang; Shenyang Li; Aarti Kalra; Monica Grafals; Didier Portilla; Deidre A MacKenna; Stuart H Orkin; Jeremy S Duffield
Journal:  Sci Transl Med       Date:  2012-02-15       Impact factor: 17.956

3.  Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis.

Authors:  Madhav C Menon; Peter Y Chuang; Zhengzhe Li; Chengguo Wei; Weijia Zhang; Yi Luan; Zhengzi Yi; Huabao Xiong; Christopher Woytovich; Ilana Greene; Jessica Overbey; Ivy Rosales; Emilia Bagiella; Rong Chen; Meng Ma; Li Li; Wei Ding; Arjang Djamali; Millagros Saminego; Philip J O'Connell; Lorenzo Gallon; Robert Colvin; Bernd Schroppel; John Cijiang He; Barbara Murphy
Journal:  J Clin Invest       Date:  2014-12-01       Impact factor: 14.808

4.  Nanodelivery of Mycophenolate Mofetil to the Organ Improves Transplant Vasculopathy.

Authors:  Mayuko Uehara; Baharak Bahmani; Liwei Jiang; Sungwook Jung; Naima Banouni; Vivek Kasinath; Zhabiz Solhjou; Jing Zhao; Farideh Ordikhani; Munhyung Bae; Nasim Annabi; Martina M McGrath; Reza Abdi
Journal:  ACS Nano       Date:  2019-09-25       Impact factor: 15.881

5.  Macrophage-to-Myofibroblast Transition Contributes to Interstitial Fibrosis in Chronic Renal Allograft Injury.

Authors:  Ying-Ying Wang; Hong Jiang; Jun Pan; Xiao-Ru Huang; Yu-Cheng Wang; Hong-Feng Huang; Ka-Fai To; David J Nikolic-Paterson; Hui-Yao Lan; Jiang-Hua Chen
Journal:  J Am Soc Nephrol       Date:  2017-02-16       Impact factor: 10.121

6.  Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.

Authors:  Dan Jane-Wit; Thomas D Manes; Tai Yi; Lingfeng Qin; Pamela Clark; Nancy C Kirkiles-Smith; Parwiz Abrahimi; Julie Devalliere; Gilbert Moeckel; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  Circulation       Date:  2013-09-17       Impact factor: 29.690

7.  Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression.

Authors:  Jonathan Merola; Melanie Reschke; Richard W Pierce; Lingfeng Qin; Susann Spindler; Tania Baltazar; Thomas D Manes; Francesc Lopez-Giraldez; Guangxin Li; Laura G Bracaglia; Catherine Xie; Nancy Kirkiles-Smith; W Mark Saltzman; Gregory T Tietjen; George Tellides; Jordan S Pober
Journal:  JCI Insight       Date:  2019-10-17

8.  Urinary vitronectin identifies patients with high levels of fibrosis in kidney grafts.

Authors:  Laura Carreras-Planella; David Cucchiari; Laura Cañas; Javier Juega; Marcella Franquesa; Josep Bonet; Ignacio Revuelta; Fritz Diekmann; Omar Taco; Ricardo Lauzurica; Francesc Enric Borràs
Journal:  J Nephrol       Date:  2020-12-04       Impact factor: 3.902

Review 9.  Challenges and considerations in diagnosing the kidney disease in deteriorating graft function.

Authors:  Henrik Ekberg; Martin E Johansson
Journal:  Transpl Int       Date:  2012-06-28       Impact factor: 3.782

Review 10.  Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.

Authors:  Myriam Dao; Helene François
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-07       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.